|Title:||Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma||Authors:||Liu J.
CHUHSING KATE HSIAO
|Issue Date:||2014||Publisher:||BMJ Publishing Group||Journal Volume:||63||Journal Issue:||10||Start page/Pages:||1648-1657||Source:||Gut||Abstract:||
Background and aims: The associations between long-term risk of hepatocellular carcinoma (HCC) and spontaneous seroclearance of HBV e antigen (HBeAg), HBV DNA and HBV surface antigen (HBsAg) have never been examined by a prospective study using serially measured seromarkers. This study aimed to assess the importance of spontaneous HBeAg, HBV DNA and HBsAg seroclearance in the prediction of HCC risk. Methods: This study included 2946 HBsAg seropositive individuals who were seronegative for antibodies against HCV and free of liver cirrhosis. Serial serum samples collected at study entry and follow-up health examinations were tested for HBeAg, HBV DNA and HBsAg. Cox proportional hazards models were used to calculate the HRs of developing HCC after seroclearance of HBV markers. Results: The HR (95% CI) of developing HCC after seroclearance of HBeAg, HBV DNA and HBsAg during follow-up was 0.63 (0.38 to 1.05), 0.24 (0.11 to 0.57) and 0.18 (0.09 to 0.38), respectively, after adjustment for age, gender and serum level of alanine aminotransferase at study entry. High HBV DNA levels at the seroclearance of HBeAg (mean±SD, 4.35±1.64 log10 IU/mL) may explain the non-significant association between HBeAg seroclearance and HCC risk. Among HBeAg seronegative participants with detectable serum HBV DNA at study entry, the lifetime (30-75-years-old) cumulative incidence of HCC was 4.0%, 6.6% and 14.2%, respectively, for those with seroclearance of both HBV DNA and HBsAg, seroclearance of HBV DNA only, and seroclearance of neither. Conclusions: Spontaneous seroclearance of HBV DNA and HBsAg are important predictors of reduced HCC risk. ? 2014, BMJ Publishing Group. All rights reserved.
|ISSN:||0017-5749||DOI:||10.1136/gutjnl-2013-305785||SDG/Keyword:||hepatitis B surface antigen; hepatitis B(e) antigen; virus DNA; biological marker; adult; Article; cancer incidence; cancer risk; clearance; female; follow up; hepatitis B; Hepatitis B virus; human; liver cell carcinoma; major clinical study; male; nonhuman; priority journal; risk assessment; risk factor; seroclearance; serology; aged; article; blood; liver tumor; middle aged; pathophysiology; proportional hazards model; Taiwan; HEPATITIS B; HEPATOCELLULAR CARCINOMA; Adult; Aged; Biological Markers; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Taiwan
|Appears in Collections:||臨床醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.